Synthesis Characterization and In Vitro Release Study of Ciprofloxacin-Loaded Chitosan Nanoparticle

被引:9
作者
Singh K. [1 ]
Mishra A. [1 ]
Singh A. [2 ]
机构
[1] School of Biochemical Engineering, Indian Institute of Technology, Banaras Hindu University, Varanasi
[2] Institute of Medical Sciences, Banaras Hindu University, Varanasi
关键词
Biodegradable polymer; Ciprofloxacin; Microbial infection; Nanoformulation; Zeta potential;
D O I
10.1007/s12668-017-0470-7
中图分类号
学科分类号
摘要
Ciprofloxacin, a poorly soluble drug-loaded chitosan nanoparticle, was prepared for the treatment of microbial infections. Nanoformulation of ciprofloxacin was prepared using 85% deacetylated chitosan as a biodegradable polymer and tripolyphosphate (TPP) as a cross-linking agent by ionotropic gelation. It was further evaluated and characterized on the basis of morphology, drug loading efficiency, X-ray diffraction, zeta potential value, Fourier transform infrared study, antimicrobial study, and also in vitro release behavior of ciprofloxacin. The FTIR spectral studies indicated that there was no interaction found between the drug and chitosan. The sample CS1 formulation was found stable with good drug entrapment efficiency, fair zeta potential value, and its size ranged between 100 and 200 nm. The in vitro study showed sustained release behavior with steady rise in cumulative drug release (> 99%) for up to about 8 h and thereafter, no significant release observed. The characterized formulations were also used to study antimicrobial activity. © 2017, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
页码:229 / 236
页数:7
相关论文
共 16 条
  • [1] Wu G., Wang G., Fu X., Zhu L., Synthesis, crystal structure, stacking effect and antimicrobial studies of novel quaternary copper (II) complex with quinolone, Molecules, 8, pp. 287-296, (2003)
  • [2] Lg S., Wn K., Development of ciprofloxacin: the USA perspective, Ciprofloxacin: 10 years of clinical experiences, pp. 1-5, (1997)
  • [3] (2009)
  • [4] Blondeau J.M., Fluoroquinolones: Mechanism of action, classification, and development of resistance, Survey of Ophthalmology, 49, 2, pp. S73-S78, (2004)
  • [5] Wilhelmus K.R., Hyndiuk R.A., Caldwell D.R., Abshire R.L., Folkens A.T., Godio L.B., 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The ciprofloxacin ointment/bacterial keratitis study group, Archives of Ophthalmology, 11, pp. 1210-1218, (1993)
  • [6] Acar J.F., Goldstein F.W., Trends in bacterial resistance to fluoroquinolones, Clinical Infectious Diseases, 24, 1, pp. S67-S73, (1997)
  • [7] Huneault L.M., Lussier B., Dubreuil P., Chouinard L., Desevaux C., Prevention and treatment of experimental osteomyelitis in dogs with ciprofloxacin-loaded crosslinked high amylose starch implants, Journal of Orthopaedic Research, 22, 6, pp. 1351-1357, (2004)
  • [8] Mehnert W., Mader K., Solid lipid nanoparticles: production, characterization and applications, Advanced Drug Delivery Reviews, 47, 2-3, pp. 165-196, (2001)
  • [9] McCarron P.A., Hall M., International Journal of Pharmaceutics, 348, pp. 115-124, (2008)
  • [10] Goya S., Rai J.K., Narang R.K., Rajesh K.S., International Journal of Pharmacy and Pharmaceutical Sciences, 2, 2, pp. 1-6, (2010)